Abstract
Defensins and cathelicidins are small cationic peptides produced by neutrophils and epithelial cells. They are highly expressed during infection. The role of constitutive and inducible antibacterial peptides has been extensively studied over the recent years; especially in the gastrointestinal (GI) tract, where the balance between the luminal bacteria and antibacterial peptides is crucial in the maintenance of a healthy GI tract. There are reports showing that the expressions of defensins and cathelicidins in the gut are dysregulated in various disease states. They could participate in the development of different disorders ranging from inflammation to cancer. Experimental findings showed that supplementation with animal cathelicidin promoted gastric ulcer healing in rats and suppressed tumorigenesis of gastric cancer in mice. Mouse cathelicidin could alleviate murine colitis by preserving mucus content and suppression of apoptosis. Other clinical applications for these antibacterial peptides are awaiting for further studies.
Keywords: Defensins, Cathelicidins, Gastritis, Gastric cancer, Inflammatory bowel diseases, neutrophils, peptides, tumorigenesis, metaplasia, magainins, ceropins, in situ, hybridization, hBD-2, hBD-3, hyperexpression, peptidoglycan
Current Pharmaceutical Design
Title: Antibacterial Peptides and Gastrointestinal Diseases
Volume: 17 Issue: 16
Author(s): Clover C. M. Wong, Lin Zhang, Shun X. Ren, Jing Shen, Ruby L. Y. Chan and Chi H. Cho
Affiliation:
Keywords: Defensins, Cathelicidins, Gastritis, Gastric cancer, Inflammatory bowel diseases, neutrophils, peptides, tumorigenesis, metaplasia, magainins, ceropins, in situ, hybridization, hBD-2, hBD-3, hyperexpression, peptidoglycan
Abstract: Defensins and cathelicidins are small cationic peptides produced by neutrophils and epithelial cells. They are highly expressed during infection. The role of constitutive and inducible antibacterial peptides has been extensively studied over the recent years; especially in the gastrointestinal (GI) tract, where the balance between the luminal bacteria and antibacterial peptides is crucial in the maintenance of a healthy GI tract. There are reports showing that the expressions of defensins and cathelicidins in the gut are dysregulated in various disease states. They could participate in the development of different disorders ranging from inflammation to cancer. Experimental findings showed that supplementation with animal cathelicidin promoted gastric ulcer healing in rats and suppressed tumorigenesis of gastric cancer in mice. Mouse cathelicidin could alleviate murine colitis by preserving mucus content and suppression of apoptosis. Other clinical applications for these antibacterial peptides are awaiting for further studies.
Export Options
About this article
Cite this article as:
C. M. Wong Clover, Zhang Lin, X. Ren Shun, Shen Jing, L. Y. Chan Ruby and H. Cho Chi, Antibacterial Peptides and Gastrointestinal Diseases, Current Pharmaceutical Design 2011; 17 (16) . https://dx.doi.org/10.2174/138161211796197025
DOI https://dx.doi.org/10.2174/138161211796197025 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Radiation Oncology and Molecular-Targeted Therapy for EGFR and its Signal Transduction Pathways: Molecular Basis and Clinical Application for Improvement of Radiotherapeutic Outcomes
Current Signal Transduction Therapy Quercetin-Phospholipid Complex: An Amorphous Pharmaceutical System in Herbal Drug Delivery
Current Drug Discovery Technologies Modulation of MMPs by Cell Surface Integrin Receptor α5β1
Anti-Cancer Agents in Medicinal Chemistry Molecular Mechanisms of Liver Cancer
Anti-Cancer Agents in Medicinal Chemistry Polymer Structures for Sensors and Actuators 1. Analyte Biosensor
Recent Patents on Materials Science A hypothesis for the role of RECK in angiogenesis
Current Vascular Pharmacology Toxicities of Targeted Agents in Advanced Renal Cell Carcinoma
Current Clinical Pharmacology Effects of PPARγ Ligands on Vascular Tone
Current Molecular Pharmacology Editorial (Thematic Issue : Recent Advances in Cancer Research: Targets and New Ligands)
Current Pharmaceutical Design Bombesin-like Peptides: Candidates as Diagnostic and Therapeutic Tools
Current Pharmaceutical Design Inhibitors of Myostatin- and Proteasome-Dependent Signaling for Attenuating Muscle Wasting
Recent Patents on Regenerative Medicine Monitoring of Treatment-Induced Apoptosis in Oncology with PET and SPECT
Current Pharmaceutical Design Chemical Modifications Designed to Improve Peptide Stability: Incorporation of Non-Natural Amino Acids, Pseudo-Peptide Bonds, and Cyclization
Current Pharmaceutical Design Docetaxel/2-Hydroxypropyl β -Cyclodextrin Inclusion Complex Increases Docetaxel Solubility and Release from a Nanochannel Drug Delivery System
Current Drug Targets Mechanisms to Inhibit Matrix Metalloproteinase Activity: Where are we in the Development of Clinically Relevant Inhibitors?
Recent Patents on Anti-Cancer Drug Discovery Advanced Neoplastic Disease as Immunologic, Endocrine and Metabolic Disorder
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Pharmaceutical Inhibition of Neddylation as Promising Treatments for Various Cancers
Current Topics in Medicinal Chemistry Heterologous Expression and Application of Multicopper Oxidases from <i>Enterococcus</i> spp. for Degradation of Biogenic Amines
Protein & Peptide Letters Research on Gastric Cancer’s Drug-resistant Gene Regulatory Network Model
Current Bioinformatics Safety of Systemic Biologic Agents in the Treatment of Non-malignant Skin Disorders
Current Drug Safety